Lineage Cell Therapeutics, Inc.
(NYSE Amex Equities : LCTX)

( )
LCTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.03%75.780.0%$2436.46m
NVAXNovavax, Inc. 2.32%177.5199.2%$1430.64m
GILDGilead Sciences, Inc. 0.26%69.181.0%$542.37m
SRNESorrento Therapeutics, Inc. -5.26%13.061.8%$499.71m
AMGNAmgen, Inc. 0.01%241.501.3%$492.24m
REGNRegeneron Pharmaceuticals, Inc. 0.60%628.292.5%$463.35m
BNTXBioNTech SE -2.12%79.580.0%$403.88m
VRTXVertex Pharmaceuticals, Inc. -1.12%270.161.9%$376.58m
VXRTVaxart, Inc. 2.33%9.890.0%$331.73m
BIIBBiogen, Inc. -0.18%275.681.6%$327.02m
ILMNIllumina, Inc. -0.19%400.003.5%$320.04m
IBIOiBio, Inc. 2.06%4.450.2%$186.19m
EBSEmergent BioSolutions, Inc. 1.84%136.986.4%$185.65m
SGENSeattle Genetics, Inc. 1.33%164.756.0%$174.39m
ALXNAlexion Pharmaceuticals, Inc. -0.18%102.572.0%$169.46m

Company Profile

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.